Abstract
Secondary hyperparathyroidism is a common consequence of chronic kidney disease. Cinacalcet (Sensipar®) is often prescribed in combination to reduce elevated levels of parathyroid hormone, calcium and phosphorus. The objective of this study was to assess the effects of concomitantly administered therapies of calcium carbonate (CaCO3; TUMS®), sevelamer hydrochloride (HCl; Renagel®) and pantoprazole sodium (Protonix®) on the pharmacokinetics and safety of cinacalcet in healthy subjects.

This publication has 20 references indexed in Scilit: